

8 Years of Spark

Hope For What's To Come



1. Progress for patients

We started 2021 on a high note: Encouraging preliminary Phase I/2 data for investigational SPK-8016 for hemophilia A bring us closer to delivering a gene therapy for patients. The 1st participant dosed in our Phase I/2 RESOLUTESM trial of SPK-3006 for late-onset Pompe disease was a pivotal milestone to bring this potential treatment to patients.

Rare Disease Week at Spark was a welcome moment to pause and unite around our shared commitment, as well as learn from advocates like Tammy Boyd and others, who asked for us to consider how we can answer the call to increase equity in healthcare.



2. Diversity, Equity, and Inclusion (DE&I) at Spark

At Spark, we strive to create a diverse workforce of unique viewpoints, experiences, and perspectives to break barriers in gene therapy and reflect the diversity of the world around us. We are actively working to identify additional concrete and measurable steps we can take to move our company forward on our journey to a more diverse, inclusive and respectful workplace for all of us.



3. Continued growth and investment in the company

250 NEW MEMBERS

joined Team Spark, all of whom share our mission of challenging the inevitability of genetic disease. We reached over 600 employees for the first time with ambitious growth plans.



4. Philadelphia biotech sector

The birthplace of cell and gene therapy is now the City of Biotech Love. Home to more than 30 companies dedicated to advancing this new age of medicine, Spark researchers and scientists are flocking here. More than a place to study, Philly is a place to launch an enriching career in biotech and benefit from a vibrant cultural hub.



5. Sparking change in the community

As our presence within Philadelphia grows, so too does our connection to the community. From charitable contributions to local organizations combatting inequities, as well as our financial contributions in response to the COVID-19 pandemic that reached more than 8 local organizations, we have doubled down on our commitment to the Philadelphia community.



6. Transformative payment plans on the horizon

We're working towards a day where healthcare professionals, payers, and policy makers can realize the potential of first-ever payment models by recognizing the unique nature of one-time gene therapies.

Last December, the Centers for Medicare and Medicaid Services issued a final rule, aimed at empowering states, manufacturers, and private payers to create new payment methods for innovative new therapies like gene therapy. Progress is coming.



7. Spark's ongoing commitment to genetic testing

Spark has been empowering communities by making the critical diagnostic step of genetic testing more accessible to those living with an inherited retinal disease (IRD).

Through initiatives like Eye Want 2 Know and ID YOUR IRD®, we're removing barriers between the IRD community and this important diagnostic tool, while also providing critical education on the importance of a genetic diagnosis for patients and families.



8. An end in sight: COVID-19 vaccine rollout has begun

While the country has suffered tremendous loss, we've also demonstrated the power of the healthcare community to test and deliver life-saving, transformative medicine in record time. It's a moment to pause and reflect on what's possible if we collaborate, embrace innovation and keep patients in the fore.

